SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Abgenix, Inc. (ABGX) -- Ignore unavailable to you. Want to Upgrade?


To: mopgcw who wrote (498)11/3/2005 2:07:40 PM
From: keokalani'nui  Respond to of 590
 
CC is very strong. Unambiguous results. Dramatic drug effect on PFS. KM curves diverge and diverge, CIs never overlap. EGFr status does not at all predict response. A few dropouts, but doubtful about any meaning to it.

This is a big, big win for P. And Perlmutter is simply outstanding. FDA is another matter of course, with the temptation to wait for 12-month survival.